Lu M. Gao
301 YanChang Road
Shanghai, 200072, China
Shanghai, 200072, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 42 publications
NT-A9, a new triazole, exhibits potent antifungal activity against Candida and Cryptococcus species through potent ergosterol biosynthesis inhibition.
Journal: Antimicrobial agents and chemotherapy
Published: August 05, 2026
Leukemia disease burden and quality of care among adolescents and young adults in China compared to global patterns: a comprehensive analysis from 1990 to 2021.
Journal: Frontiers in public health
Published: December 20, 2025
Impact of hemodynamic pattern of non-culprit vessel stenosis on the long-term prognosis in patients with acute ST-segment elevation myocardial infarction
Journal: Zhonghua xin xue guan bing za zhi
Published: March 17, 2025
Dietary tannic acid promotes intestinal clearance of C. albicans by cross-linking hyphal chitosan.
Journal: PLoS pathogens
Published: March 04, 2025
In vitro and in vivo activity of 1,2,3,4,6-O-pentagalloyl-glucose against Candida albicans.
Journal: Antimicrobial agents and chemotherapy
Published: January 24, 2025
Antifungal Tetrahydrocarbazole Compound CAR-8 Induces Endoplasmic Reticulum Stress in Candida albicans.
Journal: ACS infectious diseases
Published: July 11, 2024
Combined Transcriptome and Metabolome Analysis Reveals That the Potent Antifungal Pyrylium Salt Inhibits Mitochondrial Complex I in Candida albicans.
Journal: Microbiology spectrum
Published: February 15, 2023
Natural Products as Antifungal Agents against Invasive Fungi.
Journal: Current topics in medicinal chemistry
Published: November 20, 2022
Preclinical validation and phase I trial of 4-hydroxysalicylanilide, targeting ribonucleotide reductase mediated dNTP synthesis in multiple myeloma.
Journal: Journal of biomedical science
Published: December 28, 2021
Tunicamycin Potentiates Antifungal Drug Tolerance via Aneuploidy in Candida albicans.
Journal: mBio
Published: September 01, 2021
A novel M phase blocker, DCZ3301 enhances the sensitivity of bortezomib in resistant multiple myeloma through DNA damage and mitotic catastrophe.
Journal: Journal of experimental & clinical cancer research : CR
Published: November 30, 2019
Last Updated: 09/26/2026